Time Factor in Radiotherapy and Chemotherapy for Limited Disease Small-Cell Lung Cancer

REFERENCES

• Idhe D. C., Glatstein E., Pass HI. Principles & Practice of Oncology, 5th edition, V. T. De vita, S. Hellman, S. A. Rosenberg. Lippicont-Raven. 1997; 911–950
   Google Scholar
• Suwinski R., Lee S. P., Withers H. R. Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 1998; 40: 797–806
   PubMed Web of Science ®Google Scholar
• Turrisi A. T., 3rd., Kim K., Blum R., Sause W. T., Livingston R. B., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 1999; 340: 265–271
   PubMed Web of Science ®Google Scholar
• Arriagada R., Le Chevalier T., Pignon J. P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med. 1993; 329: 1848–1852
   PubMed Web of Science ®Google Scholar
• Bonner J. A., Sloan J. A., Shanahan T. G., Brooks B. J., Marks R. S., et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J. Clin. Oncol. 1999; 17: 2681–2691
   PubMed Web of Science ®Google Scholar
• Galani E., Ellis P. A., Harper P. G. Small-cell lung cancer, high growth rate, high response rate to chemotherapy: ideal for high-dose chemotherapy? J. Clin. Oncol. 2002; 20: 3941–3943
   Web of Science ®Google Scholar
• Videtic G. M.M., Fung K., Tomiak A. T. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer 2001; 33: 249–258
   PubMed Web of Science ®Google Scholar
• Argiris A., Murren J. R. Staging and clinical prognostic factors for small-cell lung cancer. J. Cancer 2001; 7: 437–447
   Web of Science ®Google Scholar
• Micke P., Faldum A., Metz T., Beeh K. M., Bittinger F., Hengstler J. G., Buhl R. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?. Lung Cancer 2002; 37: 271–276
   PubMed Web of Science ®Google Scholar
• Guidelines for Exercise Test Administration in Exercise Testing and Prescription, 4th ed. 1991; 73–167
   Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. J. Amer. Stat, Assoc. 1958; 53: 457–482
   Web of Science ®Google Scholar
• Cox D. R. Regression models and life-tablets. J.R. Stat. Soc. 1972; 34: 87–220
   Google Scholar
• Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Suwinski R., Sowa A., Rutkowski T., Wydmanski J., Tarnawski R., Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56: 399–412
   PubMed Web of Science ®Google Scholar
• Work E., Nielsen O. S., Bentzen S. M., Fode K., Palshof T. Randomised study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer Aarhus Lung Cancer Group. J. Clin. Oncol. 1997; 15: 3030–3037
   PubMed Web of Science ®Google Scholar
• Arriagada R., Le Chevalier T., Pignon J. P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med. 1993; 329: 1848–1852
   PubMed Web of Science ®Google Scholar
• Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J. Clin. Oncol. 1997; 15: 893–900
   PubMed Web of Science ®Google Scholar
• Komaki R., Shin D. M., Glisson B. S., Fossella F. V., Murphy W. K., et al. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 1995; 15: 807–811
   Google Scholar
• Murray N., Shah A., Osoba D., Page R., Karsai H., et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J. Clin. Oncol. 1991; 9: 1632–1638
   PubMed Web of Science ®Google Scholar
• Sekine I., Nishiwaki Y., Noda K. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann. Oncol. 2003; 14: 709–714
   PubMed Web of Science ®Google Scholar
• Glisson B. S., Kurie J. M., Perez-Soler R., Fox N. J., Murphy W. K., et al. Cisplatin, etopside, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J. Clin. Oncol. 1999; 17: 2309–2315
   PubMed Web of Science ®Google Scholar
• Pujol J. L., Douillard J. Y., Riviere A., Quoix E., Lagrange J. L., et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J. Clin. Oncol. 1997; 15: 2082–2089
   PubMed Web of Science ®Google Scholar
• Tjan-Heijnen V. C.G., Wagener D. J.T., Postmus P. E. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann. Oncol. 2002; 13: 1519–1530
   PubMed Web of Science ®Google Scholar
• Klasa R. J., Murray N., Coldman A. J. Dose-intesity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J. Clin. Oncol. 1991; 9: 499–508
   PubMed Web of Science ®Google Scholar
• Spiro S. G., Porter J. C. Lung cancer—where are we today? current advances in staging and nonsurgical treatment. Am. J. Respir. Crit. Care Med. 2002; 166: 1166–1196
   PubMed Web of Science ®Google Scholar